Aclasta patients get more insurance coverage

Published: 2010-03-16 06:58:00

Updated: 2010-03-16 06:58:00

Novartis Korea said on March 11 that health insurance coverage for Aclasta (zoledronate 5 mg) has been expanded in patients (aged over 65 years) with previous hip and vertebral fracture.

Zoledronate has been approved as a once-yearly 5 mg infusion for treatment of osteoporosis and shown signif...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK